Valneva SE Pref. Share Price Euronext Paris
Equities
VLAP
FR0011472943
Biotechnology & Medical Research
Real-time
Other stock markets
|
5-day change | 1st Jan Change | ||
- EUR | -.--% | -7.89% | -28.57% |
08:24am | Valneva: new positive data in CHIKV | CF |
05-07 | Valneva SE Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
Sales 2024 * | 190M 205M 16.33B | Sales 2025 * | 234M 252M 20.07B | Capitalization | 467M 504M 40.12B |
---|---|---|---|---|---|
Net income 2024 * | 3M 3.24M 258M | Net income 2025 * | -29M -31.28M -2.49B | EV / Sales 2024 * | 2.87 x |
Net Debt 2024 * | 77.76M 83.88M 6.68B | Net Debt 2025 * | 94.16M 102M 8.09B | EV / Sales 2025 * | 2.4 x |
P/E ratio 2024 * |
30.6
x | P/E ratio 2025 * |
-43.4
x | Employees | - |
Yield 2024 * |
-
| Yield 2025 * |
0.3% | Free-Float | 83.51% |
Latest transcript on Valneva SE Pref.
Managers | Title | Age | Since |
---|---|---|---|
Chief Executive Officer | 60 | 09/05/13 | |
Peter Buhler
DFI | Director of Finance/CFO | 54 | 28/07/21 |
Vincent Dequenne
COO | Chief Operating Officer | - | 05/07/21 |
Members of the board | Title | Age | Since |
---|---|---|---|
Kathrin Jansen
BRD | Director/Board Member | - | 20/06/23 |
James Sulat
BRD | Director/Board Member | 73 | 06/03/13 |
Jim Connolly
BRD | Director/Board Member | 59 | 23/06/22 |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+26.80% | 44.96B | |
-0.75% | 42.65B | |
+46.00% | 41.85B | |
-5.31% | 29.04B | |
+9.46% | 26.08B | |
-21.63% | 19.03B | |
+6.31% | 12.75B | |
+27.57% | 12.06B | |
-3.48% | 11.75B |
- Stock Market
- Equities
- VLA Stock
- VLAP Stock